IP Library Granted Patent US 11,225,646
Granted Patent B2
US 11,225,646 · App. 16/381,523 · Granted Jan 18, 2022

Yeast strains producing mammalian-like complex n-glycans

Inventors: Steven Christian Jozef Geysens (Wannegem-Lede, BE); Wouter Vervecken (Landskouter, BE)
Assignee: Oxyrane UK Limited
C12N9/1051C07K16/32C12N9/2402C12N9/2488C12N9/60C12N15/81C12P21/005C07K2317/14C07K2317/41C12Y204/01C12Y204/01133C12Y302/01024C12Y302/01084C12Y302/01114
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,225,646
App. No.
16/381,523
Granted
Jan 18, 2022
Kind
B2
Abstract

Described herein are methods and genetically engineered fungal cells useful for producing target molecules containing mammalian-like complex N-glycans or containing intermediates in a mammalian glycosylation pathway.

Claims (16)

1. An isolated Yarrowia lipolytica cell genetically engineered to produce proteins comprising GlcNAc2Man3GlcNAc2 N-glycans, wherein said Yarrowia lipolytica cell is genetically engineered to comprise the following alterations:

a) deficient in Outer Chain elongation (OCH1) activity;

b) deficient in Asparagine linked Glycosylation 3 (ALG3) activity;

c) recombinantly expresses an α-1,2-mannosidase inclusive of a targeting sequence to an intracellular compartment;

d) recombinantly expresses Asparagine Linked Glycosylation 6 (ALG6); and

e) recombinantly expresses a GlcNAc-transferase I and GlcNAc-transferase II,

wherein both transferases are inclusive of a targeting sequence to an intracellular compartment,

wherein as a result of said alterations, said Yarrowia lipolytica cell produces proteins comprising GlcNAc 2 Man 3 GlcNAc 2 N-glycans.

2. The Yarrowia lipolytica cell of claim 1 , wherein said genetically engineered Yarrowia lipolytica cell further comprises a nucleic acid encoding a target protein, wherein said cell produces said target protein modified to comprise said GlcNAc 2 Man 3 GlcNAc 2 N-glycans.

3. The Yarrowia lipolytica cell of claim 1 , said Yarrowia lipolytica cell further comprising a nucleic acid encoding the α and β subunits of a Glucosidase II, wherein expression of said α and β subunits of said Glucosidase II in said Yarrowia lipolytica cell produces said protein comprising said GlcNAc 2 Man 3 GlcNAc 2 N-glycans.

4. The Yarrowia lipolytica cell of claim 1 , wherein said GlcNAc-transferase I and GlcNAc-transferase II are targeted to the Golgi apparatus.

5. The Yarrowia lipolytica cell of claim 1 , wherein said α-1,2-mannosidase is targeted to the endoplasmic reticulum.

6. A pure culture comprising Yarrowia lipolytica cells, according to claim 1 .

7. The culture of claim 6 , said Yarrowia lipolytica cell further comprising a nucleic acid encoding the α and β subunits of a Glucosidase II, wherein expression of said α and β subunits of said Glucosidase II in said Yarrowia lipolytica cell produces said protein comprising said GlcNAc 2 Man 3 GlcNAc 2 N-glycans.

8. The culture of claim 6 , wherein said GlcNAc-transferase I and GlcNAc-transferase II are targeted to the Golgi apparatus.

9. The culture of claim 6 , wherein said α-1,2-mannosidase is targeted to the endoplasmic reticulum.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 30, 2024
From: OXYRANE UK LTD
To: VIB VZW
Reel/Frame 067265/0154 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 1, 2019
From: GEYSENS, STEVEN CHRISTIAN JOZEF; VERVECKEN, WOUTER
To: OXYRANE UK LIMITED
Reel/Frame 049054/0719 →
Continuity (4)
Division 14641002 · Mar 6, 2015
Continuation 13510527
Provisional Application 61262828 · Nov 19, 2009
Related Publication 20190233802A1 · Aug 1, 2019